Roivant Sciences
ROIV
500 hedge funds and large institutions have $19.7B invested in Roivant Sciences in 2026 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 201 increasing their positions, 143 reducing their positions, and 41 closing their positions.
146% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 41
41% more repeat investments, than reductions
Existing positions increased: 201 | Existing positions reduced: 143
34% more capital invested
Capital invested by funds: $14.7B → $19.7B (+$5.04B)
19% more call options, than puts
Call options by funds: $445M | Put options by funds: $372M
14% more funds holding in top 10
Funds holding in top 10: 14 → 16 (+2)
12% more funds holding
Funds holding: 445 → 500 (+55)
3.32% more ownership
Funds ownership: 74.09% → 77.41% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$220M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$137M |
| 3 |
BlackRock
New York
|
+$118M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$106M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$90.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$273M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$152M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$104M |
| 4 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$74M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$72.2M |
ROIV Hedge Fund Activity: Q2 2026 in Review
500 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q2 2026, worth a combined $19.7B — up 34% from $14.7B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new ROIV positions and 41 closed out — a net gain of 60 holders — while 201 added to existing stakes and 143 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $220M. The largest seller was Morgan Stanley, cutting an estimated $273M.
- 500 institutional investors held Roivant Sciences (ROIV) as of Q2 2026, up from 445 in Q1 2026.
- Funds reported $19.7B of Roivant Sciences stock for Q2 2026, up 34% quarter-over-quarter.
- 101 funds opened new Roivant Sciences positions in Q2 2026 and 41 closed out, a net change of +60 holders.
- The largest Roivant Sciences buyer in Q2 2026 was Goldman Sachs, an estimated $220M added.
- The largest Roivant Sciences seller in Q2 2026 was Morgan Stanley, an estimated $273M sold.
Based on aggregated 13F filings for Q2 2026.